In the context of cancer, SCGN has emerged as a novel marker for cervical neuroendocrine carcinoma and has been linked to sorafenib resistance in hepatocellular carcinoma (Yu et al., 2021; Wang et al., 2022). Here, SCGN is linked to hepatocellular carcinoma.